Document:

EX-10.12

 Exhibit 10.12 

TRANSITION AND AMENDMENT AGREEMENT 

This Transition and Amendment Agreement (this “Agreement”) is made and entered into as of December 12, 2019 (the
“Transition Date”) by and between Dr. Bhaskar Chaudhuri (the “Dr. Chaudhuri”) and Arcutis Biotherapeutics, Inc., a Delaware limited liability company (the
“Company” and together with the Dr. Chaudhuri, the “Parties” and each, a “Party”). 

RECITALS 

WHEREAS, the Parties previously entered into that certain Consulting Agreement dated August 16, 2016
(together, the “Consulting Agreement”), pursuant to which Dr. Chaudhuri agreed to serve as Chair of the Company’s board of directors (the “Board”). 

WHEREAS, the Parties have agreed to end Dr. Chaudhuri’s service as Chair of the Board,
effective as of the Transition Date. 
 WHEREAS, in connection with such transition, the Parties also
mutually desire, in order to clarify, confirm and harmonize the equity vesting arrangements that will apply to Company equity held by Dr. Chaudhuri in connection with his continued service as a member of the Board, to amend certain terms of
(1) that certain Stock Purchase Agreement dated as of August 16, 2016 (the “Stock Purchase Agreement”) and (2) that certain Notice of Stock Option Grant and Stock Option Agreement, each dated as of
March 13, 2019 (the “March 2019 Stock Option Agreement”). 
 NOW,
THEREFORE, in consideration of the foregoing recitals and the mutual promises herein contained, and for other valid consideration, the receipt and adequacy of which is hereby acknowledged, the parties hereto agree
as follows: 
 AGREEMENT 

1.    Termination of Consulting Agreement. The Parties hereby agree to terminate the
Consulting Agreement, effective as of the Transition Date. The Parties each hereby waive any notice requirements with respect to such termination under the Consulting Agreement. 

2.    Amendment to Section 5(a) of the Stock Purchase Agreement. In
connection with Dr. Chaudhuri’s continued service as a member of the Board and in order to confirm that the stock purchased pursuant to the Stock Purchase Agreement will continue to vest in connection with such Board service, the Parties
agree that Section 5(a) of the Stock Purchase Agreement is hereby amended to provide that “employed by the Company,” as such term is used in the Stock Purchase Agreement, shall mean that Dr. Chaudhuri is
rendering substantial services as an officer, employee, consultant, independent contractor or director to the Company or to any affiliate of the Company, as determined by the Board. 

3.    Amendment to Notice of Stock Option Grant Vesting Schedule. In addition, the Parties agree that
the Notice of Stock Option Grant associated with the March 2019 Stock Option Agreement is hereby amended, such that the second paragraph of the section entitled “Vesting Schedule” as set forth on the Notice of Stock Option Grant is
replaced in its entirety with the following: 
 “In addition to the vesting arrangements outlined above and notwithstanding anything to
the contrary in the Stock Option Agreement, the following vesting acceleration terms (the “Vesting Acceleration Terms”) shall apply: 

If a Change of Control occurs prior to the termination of Optionee’s arrangement to provide services to the Corporation, then the vesting
of all shares subject to the Option shall accelerate in full, effective as of the closing of the Change of Control. 

 “Change of Control” will mean the occurrence of any of the following
events: 
  

	 	(i)	 Any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”)) becomes the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing more
than 50% of the total voting power represented by the Company’s then outstanding voting securities; or 

  

	 	(ii)	 The consummation of the sale or disposition by the Company of all or substantially all of the Company’s
assets; or 

  

	 	(iii)	 The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or
consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its
parent) at least 50% of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation. 

Notwithstanding the foregoing provisions of this definition, a transaction will not be deemed a Change of Control unless the transaction
qualifies as a “change in control event” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended.” 

4.    Counterparts. This Agreement may be executed in one or more counterparts, all of which
shall be considered one and the same agreement and shall become effective when one or more counterparts have been signed and delivered by each of the parties hereto. 

5.    Governing Law. This Agreement shall be construed exclusively in accordance with, and
governed in all respects exclusively by, the internal laws of the State of California (without giving effect to principles of conflicts of laws). 

6.    Entire Agreement. This Agreement sets forth the entire agreement and understanding between the
parties hereto concerning the subject matter herein, and supersedes all prior written and oral understandings relating to such subject matter. 

[SIGNATURE PAGE FOLLOWS] 

  
 2 

 IN WITNESS WHEREOF, the
parties hereto have executed this Transition and Amendment Agreement as of the date first written above. 
  

			
	DR. CHAUDHURI
		
	By:	 	 /s/ Bhaskar Chaudhuri

	Name:	 	Bhaskar Chaudhuri
	
	COMPANY
		
	By:	 	 /s/ Todd Franklin Watanabe

	Name:	 	Todd Franklin Watanabe
	Title:	 	Chief Executive Officer

 [SIGNATURE PAGE TO TERMINATION
AGREEMENT]EX-10.13

 Exhibit 10.13 

OPTION NOTICE AND AMENDMENT NO. 2 TO 

EXCLUSIVE OPTION AND LICENSE AGREEMENT 

THIS OPTION NOTICE AND AMENDMENT NO. 2 (this “Notice and Amendment”) to the Exclusive Option and License Agreement dated
as of January 4, 2018 and amended on June 26, 2019 (the “Agreement”), by and between Arcutis Biotherapeutics, Inc., a United States corporation incorporated in the State of Delaware
(“Arcutis”) and Jiangsu Hengrui Medicine Co., Ltd., a Chinese corporation (“Hengrui”) is entered into as of 5 December, 2019 (the “Effective Date”). 

RECITALS 

A.    Pursuant to the Agreement, Hengrui granted Arcutis an exclusive option to obtain an exclusive license under the
Licensed Technology for the development of topical therapeutic products. 
 B.    Arcutis now elects to exercise the
Option as set forth in the Agreement, and the parties desire to enter into this Notice and Amendment to confirm the exercise of the Option and amend the term “Territory” under the Agreement. 

NOW, THEREFORE, in consideration of the mutual promises contained herein, the parties agree as follows: 

 

	1.	 Definitions. Except as defined in this Notice and Amendment, the capitalized terms used herein shall
have the same meanings as ascribed to them in the Agreement. 

  

	2.	 Exercise of Option.  

 

	 	a.	 Arcutis hereby exercises the Option in accordance with Section 2.6 of the Agreement.

  

	 	b.	 Arcutis has paid Forty Thousand Dollars ($40,000) of withholding taxes to the U.S. Department of Treasury
Internal Revenue Service on Hengrui’s behalf in addition to and in respect of the Upfront Payment paid to Hengrui on January 30, 2018, and is required to withhold One Hundred and Fifty Thousand Dollars ($150,000) of withholding taxes on
Hengrui’s behalf for the Option Exercise Payment upon the exercise of the Option. Accordingly, the parties agree that One Hundred and Ninety Thousand Dollars ($190,000) shall be deducted from the payment to Hengrui for Option Exercise Payment.

  

	 	c.	 Upon execution of this Notice and Amendment by the parties, Arcutis shall pay the remaining Option Exercise
Payment in the amount of One Million Three Hundred and Ten Thousand Dollars ($1,310,000) to Hengrui. 

  

	3.	 Amendment. Section 1.36 (Territory) is hereby deleted and replaced with the following:

 “Territory” means (a) the United States, (b) Canada, (c) Japan, (d) the countries
of the European Union as of the Effective Date (including the United Kingdom and all of its component nations, as of the Effective Date), whether or not remaining in the European Union following the Effective Date, (e) any other country that
becomes part of the European Union at any time following the Effective Date, and (f) any territory or possession of any of the foregoing. 
  

	4.	 Effect of Notice and Amendment. The parties agree that this Notice and Amendment shall be deemed to have
been in full force and effective as of the Effective Date. All the terms and conditions of the Agreement shall continue in full force and effect except as modified by the terms of this Notice and Amendment. 

	5.	 Counterparts. This Notice and Amendment may be executed in counterparts, each of which shall be deemed
an original and all of which taken together constitute one instrument. 

 IN WITNESS WHEREOF, Arcutis and Hengrui have caused this Notice
and Amendment to be executed and delivered by their respective officers thereunto duly authorized, all as of the Effective Date. 
  

			
	Arcutis Biotherapeutics, Inc.	  	Jiangsu Hengrui Medicine Co., Ltd.
		
	By: /s/ Frank
Watanabe                                    	  	By: /s/ Lianshan
Zhang                                    
	Name: Frank Watanabe	  	Name: Lianshan Zhang
	Title: President and CEO	  	Title: SVP
	Date: 5 December 2019	  	Date: 2019/12/06ex_168604.htm

Exhibit 10.1

 

 

MEMBERSHIP INTEREST PURCHASE AGREEMENT

 

THIS MEMBERSHIP INTEREST PURCHASE AGREEMENT (this “Agreement”) is made and entered into on January 2, 2020, by and between Ergon Terminaling, Inc. (“Ergon”) and Blueknight Energy Partners, L. P. (“BKEP”).

 

W I T N E S S E T H:

 

WHEREAS, Ergon owns all of the issued and outstanding membership interests of DEVCO; and

 

WHEREAS, Ergon desires to sell, and BKEP desires to purchase in exchange for cash, all of the issued and outstanding membership interests of DEVCO owned by Ergon (“Membership Interests”).

 

NOW, THEREFORE, in consideration of the mutual covenants, agreements and understandings contained herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the Parties hereto hereby agree as follows:

 

	 	
			1.

				
			Membership Interest Purchase.

			

 

(a)     On the terms and subject to the conditions set forth in this Agreement, on the Closing Date, BEKP shall purchase from Ergon and Ergon shall sell, assign convey, and transfer to BKEP, all of the Membership Interests, free and clear of any liens, restrictions on transfer (other than restrictions arising under the law), options, rights, calls commitments, proxies or other contract rights.

 

(b)     In consideration of the purchase of the Membership Interest by BKEP, BKEP shall pay to Ergon the Purchase Price as calculated in the formula set forth on Schedule 1.

 

	 	
			2.

				Purchase Price.

 

(a)     The Purchase Price for the Membership Interests shall be computed by taking Ergon’s total investment in the STACK Pipeline Project including, but not limited to, working capital, cash, out-of-pocket expenses, engineering, project management, legal and accounting costs, plus interest at the rate of nine percent (9%) per annum compounded annually on each component from the last day of the month in which the expenditure is made less any distributions from the Cimarron Express Pipeline, LLC (adjusted for income taxes)( the “Purchase Price”). Reasonable compensation for the time reasonably expended by Ergon personnel on the STACK Pipeline Project shall be a component of the Purchase Price and shall be computed in accordance with Schedule 1.

 

(b)     Not later than five (5) Business Days prior to the Closing Date, Ergon shall deliver to BKEP a written statement showing Ergon’s good faith calculation of the Purchase Price.

 

(c)     The Purchase Price shall not include any working capital in DEVCO. Immediately prior to the Closing, Ergon may cause DEVCO to distribute to Ergon all cash or cash equivalents held and owned by DEVCO.

 

	 	
			3.

				Closing.

 

(a)     Closing Date. The closing of the transactions contemplated by this Agreement (the “Closing”) shall take place by the electronic exchange of the appropriate documentation, with any originals as may be required to be exchanged by mail promptly following the electronic closing, not later than the sixtieth (60th) day following exercise of the Put or the Call as defined in that certain Agreement between the parties dated May 9th, 2018 or at such other place or on such other date as may be mutually agreeable to BKEP and Ergon. The date and time of the Closing are herein referred to as the “Closing Date”.

 

1

 

 

(b)     Closing Deliveries. Subject to the conditions set forth in this Agreement, each of the Parties shall deliver to the other the following on the Closing Date (the “Closing Deliveries”):

 

(i)     Ergon Deliveries. At Closing, Ergon shall deliver to BKEP:

 

	 	
			(1)

				
			all corporate books and records of the DEVCO;

			

 

	 	
			(2)

				
			a copy of the signed entry into the Members’ Registry Book of DEVCO, duly recorded into such book, certifying the transfer of ownership of all of DEVCO’s Membership Interests to Buyer;

			

 

	 	
			(3)

				
			a resolution duly adopted at a meeting or by unanimous written consent of Ergon pursuant to which Ergon, approved the transfer to BKEP of the Membership Interests held by Ergon;

			

 

	 	
			(4)

				
			the resignation letters of the managers of DEVCO duly signed and effective as of the Closing Date;

			

 

(ii)     BKEP Deliveries. At Closing, BKEP shall deliver to Ergon:

 

	 	
			(1)

				
			duly adopted corporate resolutions of DEVCO electing managers to succeed Ergon’s resigning managers effective as of the Closing Date;

			

 

	 	
			(2)

				
			the Purchase Price by wire transfer of immediately available funds to an account or accounts designated by Ergon.

			

 

	 	
			4.

				Conditions to BKEP's Obligation to Close.

 

The obligation of BKEP to consummate the transactions contemplated by this Agreement is subject to the fulfillment of the following conditions as of the Closing Date:

 

(a)     Ergon representations shall be true and correct in all material respects as of the date of this Agreement and as of the Closing Date.

 

(b)     Ergon shall have performed and complied in all material respects with all of the covenants and agreement required to be performed under this Agreement.

 

	 	
			5.

				Conditions to Ergon's Obligation to Close.

 

The obligation of Ergon to consummate the transactions contemplated by this Agreement is subject to the fulfillment of the following conditions as of the Closing Date:

 

2

 

 

(a)     BKEP representations shall be true and correct in all material respects as of the date of this Agreement and as of the Closing Date.

 

(b)     BKEP shall have performed and complied in all material respects with all of the covenants and agreement required to be performed under this Agreement including delivery of the Purchase Price.

 

	 	
			6.

				Ergon Representations.

 

Ergon represents and warrants as follows:

 

(a)     DEVCO is duly organized, validly existing, and in good standing under the laws of the State of Delaware.

 

(b)     The execution, delivery and performance by Ergon of this Agreement, and the consummation of the transactions contemplated hereby, do not and will not (i) result in a violation or breach of any provision of the respective organizational documents of Ergon or DEVCO, (ii) result in a violation or breach of any provision of any law or governmental order applicable to Ergon or DEVCO; or (iii) require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default under or result in the acceleration of any material contract. No consent, approval, license, governmental order, declaration or filing with, or notice to, any governmental authority is required by or with respect to Ergon or DEVCO in connection with the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby.

 

(c)     DEVCO owns fifty percent (50%) of the authorized and outstanding member interests in Cimarron Express Pipeline, LLC. The limited liability company agreement of Cimarron Express Pipeline, LLC has not been materially amended, modified, or otherwise changed since it was executed.

 

	 	
			7.

				BKEP Representations.

 

BKEP represents and warrants as follows:

 

(a)      BKEP is duly organized, validly existing, and in good standing under the laws of the State of Delaware, with full power and authority to enter into this Agreement and to perform its obligations hereunder.

 

(b)      BKEP has all requisite power, authority and legal capacity to execute and deliver this Agreement and to consummate the transactions contemplated hereby and thereby. Each of the Conflicts Committee of the Board of Directors and the Board of Directors of the General Partner of BKEP has duly approved this Agreement and has duly authorized the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby. No other corporate proceedings on the part of BKEP is necessary to approve and authorize the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby. This Agreement has been duly executed and delivered by BKEP and constitutes the valid and binding agreement of BKEP, enforceable against BKEP in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar applicable law affecting creditors’ rights generally and by general principles of equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

 

3

 

 

	 	
			8.

				Indemnification.

 

(a)      The representation and warranties contained herein shall survive Closing and shall remain in full force and effect for six (6) months from the Closing Date.

 

(b)      Ergon shall indemnify BKEP against and shall hold BKEP harmless from an against any and all losses incurred or sustained by or imposed upon BKEP based upon, arising out of with respect to or by reason of any material inaccuracy in or breach any representation set forth in Section 6.

 

(c)      BKEP shall indemnify Ergon against and shall hold Ergon harmless from an against any and all losses incurred or sustained by or imposed upon Ergon based upon, arising out of with respect to or by reason of any material inaccuracy in or breach any representation set forth in Section 7.

 

	 	
			9.

				Notices

 

All notices and communications required or permitted to be given hereunder shall be sufficient in all respects (a) if given in writing and delivered personally, (b) if sent by overnight courier, (c) if mailed by U.S. Express Mail or by certified or registered United States Mail with all postage fully prepaid, or (d) sent by electronic transmission (provided any such electronic transmission is confirmed either orally or by written confirmation) and, in each case, addressed to the appropriate Party hereto at the address for such Party shown below or at such other address as such Party shall have theretofore designated by written notice delivered to the Party giving such notice:

 

BKEP:

 

Blueknight Energy Partners, L. P.

6060 American Plaza, Suite 600

Tulsa, OK 74135

Attention:     Mark Hurley

Telephone: 713-632-8805

E-mail:      mhurley@bkep.com

 

With a copy to:

 

Blueknight Energy Partners, L.P.

6060 American Plaza, Suite 600

Tulsa, OK 74135

Attention:     Joel W. Kanvik

Telephone:     918-237-4030

E-mail: jkanvik@bkep.com

 

 

4

 

 

 

Ergon:

Ergon Terminaling, Inc.

Attention:     Emmitte J. Haddox

2829 Lakeland Drive, Suite 2000

Flowood, MS 39232

Telephone:     601-933-3000

E-mail: Emmitte.Haddox@ergon.com

 

With a copy to:

 

Watson Heidelberg, PLLC

2829 Lakeland Drive, Suite 1502

Flowood, MS 39232

Attention:     J. Kevin Watson                    

Telephone:     601-939-8900

E-Mail: kwatson@whjpllc.com

 

	 	
			10.

				Governing Law.

 

THIS AGREEMENT AND THE LEGAL RELATIONS BETWEEN THE PARTIES SHALL BE GOVERNED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE, EXCLUDING ANY CONFLICTS OF LAW RULE OR PRINCIPLE THAT MIGHT REFER CONSTRUCTION OF SUCH PROVISIONS TO THE LAWS OF ANOTHER JURISDICTION.

 

	 	
			11.

				Entirety of Agreement.

 

THIS AGREEMENT CONSTITUTES THE ENTIRE AGREEMENT BETWEEN THE PARTIES REGARDING THE INVESTMENT IN DEVCO AND SUPERSEDES ALL OTHER PRIOR AND CONTEMPORANEOUS AGREEMENTS, WHETHER WRITTEN OR ORAL, BETWEEN THE PARTIES AND RELATED THERETO. NO VARIATIONS, MODIFICATIONS, OR CHANGES SHALL BE BINDING UPON A PARTY UNLESS EFFECTUATED BY AN INSTRUMENT IN WRITING EXECUTED BY A DULY AUTHORIZED OFFICER OR A DULY AUTHORIZED AGENT FOR IT.

 

	 	
			12.

				Captions or Headings.

 

The headings appearing at the beginning of each Section are all inserted and included solely for convenience and shall never be considered or given any effect in construing this Agreement, or any provision or provisions hereof, or in connection with determining the duties, obligations, or liabilities of the Parties or in ascertaining intent, if any question of intent should arise.

 

	 	
			13.

				Assignment.

 

This Agreement and its attendant rights may not be assigned, transferred, subcontracted, or otherwise conveyed by either Party without the express written consent of the other Party; provided however, a Party may assign its rights and obligations under this Agreement to an Affiliate with the prior consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. Any such assignment without consent shall be void.

 

5

 

 

	 	
			14.

				Duplicate Originals.

 

This Agreement is executed in duplicate originals, with one original to be retained by Ergon and one original to be retained by BKEP.

 

 

	 	
			15.

				No Third-Party Beneficiary.

 

Nothing in this Agreement, express or implied, shall entitle any Person other than the Parties or their respective successors and permitted assigns to any claim, remedy or right of any kind; provided that only a Party and its successors and permitted assigns will have the right to enforce the provisions of this Agreement on its own behalf.

 

 

	 	
			16.

				Severability.

 

If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of Law or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not materially affected in any manner adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible.

 

	 	
			17.

				Waiver.

 

No waiver by either Party of the performance of any provision, condition or requirement in this Agreement will be deemed to be a waiver of, or in any manner release the other Party from performance of any other provision, condition or requirement in this Agreement; and it will not be deemed to be a waiver of, or in any manner release the other Party from, future performance of the same provision, condition or requirement; and no delay or omission of a Party in exercising any right under this Agreement will in any manner impair the exercise of any such right or any like right accruing to it thereafter. No waiver will be effective unless made in writing and signed by the Party to be charged with such waiver.

 

	 	
			18.

				Exhibits and Schedules.

 

In the event of any conflict between the terms and conditions of this Agreement and the terms and conditions of any Exhibit or Schedule, the terms and conditions of this Agreement govern and control.

 

6

 

 

 

	 	
			19.

				Joint Efforts.

 

This Agreement will be considered for all purposes as prepared through the joint efforts of the Parties and will not be construed against one Party or the other as a result of the preparation, submittal or other event of negotiation, drafting or execution of the Agreement.

 

	 	
			20.

				Counterparts.

 

This Agreement may be executed in any number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all of such counterparts shall constitute for all purposes one agreement. Any signature hereto delivered by a Party by facsimile or other electronic transmission shall be deemed an original signature hereto.

 

IN TESTIMONY WHEREOF, witness the hands and seals of the Parties as of the date of this Agreement.

 

	
			 

				Blueknight Energy Partners, L. P.
	 	 
	
			By:

				
			/s/ Mark A. Hurley

			
	
			Name:

				Mark A. Hurley
	Title:	CEO

 

 

	
			Ergon Terminaling, Inc.

			
	 	 
	
			By:

				
			/s/ Kris Patrick

			
	
			Name:

				Kris Patrick
	Title:	EVP-COO

 

 

 

 

 

 

 

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]